BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 20154262)

  • 1. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction.
    Tan SM; Zhang Y; Connelly KA; Gilbert RE; Kelly DJ
    Am J Physiol Heart Circ Physiol; 2010 May; 298(5):H1415-25. PubMed ID: 20154262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble transforming growth factor-beta1 receptor II might inhibit transforming growth factor-beta-induced myofibroblast differentiation and improve ischemic cardiac function after myocardial infarction in rats.
    Lian R; Chen Y; Xu Z; Zhang X
    Coron Artery Dis; 2010 Sep; 21(6):369-77. PubMed ID: 20613497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
    See F; Thomas W; Way K; Tzanidis A; Kompa A; Lewis D; Itescu S; Krum H
    J Am Coll Cardiol; 2004 Oct; 44(8):1679-89. PubMed ID: 15489104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of TGF-beta1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats.
    Matsumoto-Ida M; Takimoto Y; Aoyama T; Akao M; Takeda T; Kita T
    Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H709-15. PubMed ID: 16183734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis.
    Petersen M; Thorikay M; Deckers M; van Dinther M; Grygielko ET; Gellibert F; de Gouville AC; Huet S; ten Dijke P; Laping NJ
    Kidney Int; 2008 Mar; 73(6):705-15. PubMed ID: 18075500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
    Long L; Crosby A; Yang X; Southwood M; Upton PD; Kim DK; Morrell NW
    Circulation; 2009 Feb; 119(4):566-76. PubMed ID: 19153267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activin type II receptor ligand signaling inhibition after experimental ischemic heart failure attenuates cardiac remodeling and prevents fibrosis.
    Castillero E; Akashi H; Najjar M; Ji R; Brandstetter LM; Wang C; Liao X; Zhang X; Sperry A; Gailes M; Guaman K; Recht A; Schlosberg I; Sweeney HL; Ali ZA; Homma S; Colombo PC; Ferrari G; Schulze PC; George I
    Am J Physiol Heart Circ Physiol; 2020 Feb; 318(2):H378-H390. PubMed ID: 31886717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse.
    LaPointe MC; Mendez M; Leung A; Tao Z; Yang XP
    Am J Physiol Heart Circ Physiol; 2004 Apr; 286(4):H1416-24. PubMed ID: 14670812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ataxia telangiectasia-mutated kinase deficiency exacerbates left ventricular dysfunction and remodeling late after myocardial infarction.
    Daniel LL; Scofield SL; Thrasher P; Dalal S; Daniels CR; Foster CR; Singh M; Singh K
    Am J Physiol Heart Circ Physiol; 2016 Aug; 311(2):H445-52. PubMed ID: 27288435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing.
    Hao J; Ju H; Zhao S; Junaid A; Scammell-La Fleur T; Dixon IM
    J Mol Cell Cardiol; 1999 Mar; 31(3):667-78. PubMed ID: 10198196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction.
    Ikeuchi M; Tsutsui H; Shiomi T; Matsusaka H; Matsushima S; Wen J; Kubota T; Takeshita A
    Cardiovasc Res; 2004 Dec; 64(3):526-35. PubMed ID: 15537506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5.
    Engebretsen KV; Skårdal K; Bjørnstad S; Marstein HS; Skrbic B; Sjaastad I; Christensen G; Bjørnstad JL; Tønnessen T
    J Mol Cell Cardiol; 2014 Nov; 76():148-57. PubMed ID: 25169971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qiliqiangxin Attenuates Cardiac Remodeling via Inhibition of TGF-β1/Smad3 and NF-κB Signaling Pathways in a Rat Model of Myocardial Infarction.
    Han A; Lu Y; Zheng Q; Zhang J; Zhao Y; Zhao M; Cui X
    Cell Physiol Biochem; 2018; 45(5):1797-1806. PubMed ID: 29510381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction.
    Zhang Y; Elsik M; Edgley AJ; Cox AJ; Kompa AR; Wang B; Tan CY; Khong FL; Stapleton DI; Zammit S; Williams SJ; Gilbert RE; Krum H; Kelly DJ
    Int J Cardiol; 2013 Sep; 168(2):1174-85. PubMed ID: 23219315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction.
    Ellmers LJ; Scott NJ; Medicherla S; Pilbrow AP; Bridgman PG; Yandle TG; Richards AM; Protter AA; Cameron VA
    Endocrinology; 2008 Nov; 149(11):5828-34. PubMed ID: 18653707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Icariin improves cardiac function and remodeling via the TGF-β1/Smad signaling pathway in rats following myocardial infarction.
    Jia J; Zhao XA; Tao SM; Wang JW; Zhang RL; Dai HL; Zhang XJ; Han MH; Yang B; Li Y; Li JT
    Eur J Med Res; 2023 Dec; 28(1):607. PubMed ID: 38115154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.
    Laping NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA
    Mol Pharmacol; 2002 Jul; 62(1):58-64. PubMed ID: 12065755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure.
    Okada H; Takemura G; Kosai K; Li Y; Takahashi T; Esaki M; Yuge K; Miyata S; Maruyama R; Mikami A; Minatoguchi S; Fujiwara T; Fujiwara H
    Circulation; 2005 May; 111(19):2430-7. PubMed ID: 15867170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy.
    Connelly KA; Kelly DJ; Zhang Y; Prior DL; Advani A; Cox AJ; Thai K; Krum H; Gilbert RE
    Circ Heart Fail; 2009 Mar; 2(2):129-37. PubMed ID: 19808328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats.
    Deten A; Hölzl A; Leicht M; Barth W; Zimmer HG
    J Mol Cell Cardiol; 2001 Jun; 33(6):1191-207. PubMed ID: 11444923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.